Thyrocare Technologies Limited , a leading diagnostics company, has initiated a postal ballot process to seek shareholder approval for the appointment of Mr. Alok Kumar Jagnani as a Non-Executive & Non-Independent Director. This move comes as part of the company's efforts to strengthen its board with experienced professionals.

Key Highlights of the Appointment

• Board Recommendation: The Board of Directors, based on the Nomination and Remuneration Committee's recommendation, approved Jagnani's appointment as an Additional Director on July 24, 2025.
• Shareholder Approval: The company is now seeking shareholder approval through a postal ballot, as required by regulations.
• E-voting Period: Shareholders can cast their votes electronically from August 28, 2025, to September 26, 2025.

About Alok Kumar Jagnani

Mr. Jagnani brings over 20 years of experience to Thyrocare's board:

• Professional Background: A Chartered Accountant with extensive experience in finance, risk management, and corporate assurance across manufacturing and service sectors.
• Core Competencies: Expertise in corporate assurance, risk management, internal controls, SOX compliance, and financial control for large-scale operations exceeding ₹3,000.00 crores.
• Additional Skills: Proficient in project finance, business transformation initiatives, and ERP implementations.

Recent Transition

• Prior to this appointment, Jagnani served as Thyrocare's Chief Financial Officer from August 9, 2023, to July 23, 2025.
• He has now been elevated to the role of Group CFO at API Holdings Limited, Thyrocare's ultimate holding company.

Board Committees

Upon appointment, Jagnani will serve as a member of the:

• Corporate Social Responsibility Committee
• Stakeholders' Relationship Committee
• Risk Management Committee

Financial Compensation

• As a Non-Executive Director, Jagnani will not receive any remuneration for this role.
• In his previous capacity as CFO, he earned ₹1,18,82,260.00 for the financial year 2024-25 and ₹51,57,024.00 for 2025-26 (until July 23, 2025).

Shareholding

Jagnani holds a stake in the company, with 2,443 equity shares (including shares held by his spouse) as of the latest disclosure.

The postal ballot notice emphasizes the Board's opinion that Jagnani's appointment would be beneficial to Thyrocare, considering his skills, knowledge, and rich experience in the field. Shareholders are encouraged to participate in the e-voting process to cast their votes on this important appointment.

Thyrocare Technologies continues to evolve its leadership structure, aiming to enhance its strategic capabilities in the competitive diagnostics sector.

Thyrocare Technologies has announced a significant leadership change that will impact both the company and its ultimate holding company, API Holdings Limited. Rahul Guha, the current Managing Director and CEO of Thyrocare, is set to take on an additional role as the Managing Director and CEO of API Holdings, effective August 27, 2025.

Dual Leadership Role

The Board of Directors of API Holdings, based on the recommendation of its Nomination and Remuneration Committee, has approved Guha's appointment to this dual leadership position. This move is part of an ongoing leadership development initiative across the group companies.

Continuity at Thyrocare

Guha will continue in his current role as Managing Director and CEO of Thyrocare Technologies Limited. He will be responsible for discharging his duties at Thyrocare while taking on the additional responsibilities at API Holdings.

Previous Experience

Prior to this appointment, Guha was serving as President - Operations at API Holdings. In this role, he focused on driving synergies across API Holdings and its group companies, which likely contributed to his selection for this expanded leadership position.

Leadership Restructuring at API Holdings

As part of this leadership restructuring, Siddharth Shah, the current Managing Director and CEO of API Holdings, will be re-designated as Director and Vice Chairman of the company, also effective from August 27, 2025.

Official Notifications

Thyrocare Technologies Limited has officially informed the stock exchanges about this development. The company received an intimation from API Holdings on August 6, 2025, detailing the changes in leadership.

This strategic move appears to be aimed at strengthening the synergies between Thyrocare Technologies and its parent company, API Holdings, by having a single executive oversee both entities. The impact of this dual leadership on the operations and performance of both companies will be closely watched by industry observers in the coming months.